Precision anesthesia and pharmacogenomics: a scoping review of personalized drug response
Frontiers in Anesthesiology · 30.01.2026 · 5
DOI: 10.3389/fanes.2026.1727481 ↗Kurz gefasst
Scoping Review in der Zeitschrift Frontiers in Anesthesiology, online erschienen am 30.01.2026. Verfasst von Sarina Nikzad und 2 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anesthetic agent selection and dosing have historically relied on empirical models without taking into account inter-individual variability in drug response, leading to adverse drug reactions (ADRs). Precision medicine, specifically leveraging pharmacogenomics (PGx), offers a paradigm shift toward personalized anesthesia, enhancing efficacy and safety.
Methods
This scoping review synthesized literature from 2015 to 2025, using systematic database searches and Artificial Intelligence (AI)-powered tools, to identify the most extensively studied genetic variants impacting the pharmacokinetics and pharmacodynamics of common perioperative medications.
Results
Key genetic variants in metabolic enzymes, transporters, and receptors significantly influence anesthetic outcomes. Examples include Reduced Metabolism/Prolonged Effects: Variations in CYP3A4/5 and POR alter midazolam metabolism, risking prolonged sedation. CYP2B6*6 is associated with decreased clearance of propofol and ketamine. BChE deficiency causes significantly prolonged paralysis with succinylcholine. Altered Efficacy/Increased Dose Requirements: OPRM1 118 A > G (G-allele) carriers show a blunted response to morphine, requiring higher doses. CYP2D6 ultra-rapid metabolizers (UMs) can have reduced efficacy of ondansetron and risk toxicity from pro-drugs like codeine and tramadol. Pathogenic mutations in RYR1 and CACNA1S identify patients susceptible to Malignant Hyperthermia from volatile anesthetics. Drug-Drug Interactions (DDIs): PGx overlaps with chronic medications (e.g., antidepressants, beta-blockers) that inhibit CYP2D6 , creating a phenoconversion risk that functionally mimics a Poor Metabolizer (PM) phenotype, drastically altering opioid efficacy.
Conclusions
PGx holds transformative potential for the field of anesthesiology by offering actionable insights for drug selection and dose adjustment to mitigate ADRs and optimize pain control.
Zitieren
APA
Nikzad, S., Elvir-Lazo, O. L., & Wong, R. (2026). Precision anesthesia and pharmacogenomics: a scoping review of personalized drug response. Frontiers in Anesthesiology, 5. https://doi.org/10.3389/fanes.2026.1727481
Vancouver
Nikzad S, Elvir-Lazo OL, Wong R. Precision anesthesia and pharmacogenomics: a scoping review of personalized drug response. Frontiers in Anesthesiology. 2026;5. doi:10.3389/fanes.2026.1727481
BibTeX
@article{Nikzad2026,
author = {Nikzad, Sarina and Elvir-Lazo, Ofelia Loani and Wong, Robert},
title = {Precision anesthesia and pharmacogenomics: a scoping review of personalized drug response},
journal = {Frontiers in Anesthesiology},
year = {2026},
volume = {5},
doi = {10.3389/fanes.2026.1727481}
}
EUVIMED